J Cancer 2017; 8(8):1324-1329. doi:10.7150/jca.18086
Association of MAGE A1-6 Expression with Lung Cancer Progression
1. Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea;
2. Respiratory Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea;
3. Department of Laboratory Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea;
4. Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
* These two authors contributed equally to this work.
# Current address: Department of Thoracic and Cardiovascular Surgery, Korea University Anam Hospital, Seoul, Republic of Korea.
Yi E, Chang JE, Leem C, Jeon CH, Jheon S. Association of MAGE A1-6 Expression with Lung Cancer Progression. J Cancer 2017; 8(8):1324-1329. doi:10.7150/jca.18086. Available from http://www.jcancer.org/v08p1324.htm
The melanoma-associated antigen (MAGE) genes are known to be expressed in various kinds of tumors including lung cancer. Although they are studied as targets for immunotherapy and tools for early detection of lung cancer, the correlation between MAGE expression and the prognosis in lung cancer has not been clarified. In this study, we evaluated the relationship between MAGE A1-6 gene expression and the clinical prognosis in lung cancer.
Bone marrow aspirations were performed in 60 patients who were diagnosed as lung cancer and underwent lung cancer surgery between 2007 and 2008. Each bone marrow was examined using nested reverse transcription- polymerase chain reaction (RT-PCR) with the MAGE common primer to detect MAGE A1-6. Overall survival rate, disease-free survival rate, recurrence, and distant metastasis were reviewed retrospectively. Survival periods were analyzed using SPSS ver. 20.0.
Of the total 60 lung cancer patients, 9 patients (15%) had MAGE A1-6. MAGE A1-6-positive patients showed poor overall survival and overall disease-free survival rates (43.8 ± 26.1, 43.2 ± 26.9 months, respectively) compared with MAGE A1-6-negative patients (54.4 ± 17.2, 44.8 ± 22.1 months, respectively). No significant difference was shown in either survival rates.
In conclusion, MAGE A1-6 expression of bone marrow in lung cancer patients correlated with poor survival rates. We suggest that MAGE A1-6 may be considered as a novel prognostic factor for lung cancer which leads to effective follow-up and treatment.
Keywords: Lung Cancer, MAGE A1-6, Bone Marrow, Survival Rate, Recurrence, Distant Metastasis.